Scroll

Research

...in delivering tomorrow's technology today through our FDA-monitored clinical research trials.



On This Page

Sioux Falls Research

CATARACT/LENS Studies

BVI Finevision

  • Good Candidate: Subjects 22 years and older considering intraocular surgery to remove your cataracts
  • About study: The purpose of the study is to evaluate the safety of the FINEVISION HP Trifocal IOL and how well it works compared to an FDA-approved intraocular lens
  • Which eye: Both eyes
  • How long is study: 12 months
  • Number of visits: 11 visits
  • Cost to the patient: The study visits, study IOLs and study-related procedures, other than your cataract surgery, will be provided at no cost to you or your insurance company.
  • Compensation: Up to $550 for completed visits
  • Co-management: None
  • Sioux Falls Lead Contact: Elle Malmanger elle.malmanger@vancethompsonvision.com 605-361-7083

RxSight 029

  • Good Candidate: Subjects Age between 40 and 80 with cataracts affecting their vision
  • About Study: The purpose of this study is to further evaluate the safety of an approved intra-ocular lens (IOL) called RxSight Light Adjustable Lens (LAL) and a device called Light Delivery Device (LDD)
  • Which eye: OD or OS, randomized
  • How long is study: 6 months
  • How many visits: 7 visits for control group and up to 12 for LAL group
  • Cost to patient/financial: standard cataract surgery billed to insurance, all study related exams and procedures are no additional cost (i.e. LAL LDD treatments and lock-ins)
  • Compensation: $450 total, no mileage, fine tune included
  • Co-management: none
  • Sioux Falls Lead coordinator: Rebekah Tuchscherer rebekah.tuchscherer@vancethompsonvision.com 605-705-3517
  • Sioux Falls Secondary coordinator: Gabrielle Malmanger elle.malmanger@vancethompsonvision.com 605-371-7083

KOWA

  • Good Candidate: At least 18 years old without clinically significant ocular conditions, other than cataracts, that require medication or surgery and are scheduled to undergo standalone cataract surgery. All lens packages eligible. Patients being treated for glaucoma with single medication are eligible (CAIs and ROCK inhibitors excluded).
  • About Study: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week treatment and 14-week extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery. This study is to determine if subjects randomized to K-321 have less natural ECC loss after cataract surgery.
    Which eye: One eye - determined by investigator
    How long is study: 4-6 months
    How many visits: 9-11 visits
    Cost to patient: Patient and insurance company responsible for costs associated with cataract surgery. Patients receive Ripasudil drops free of charge.
    Compensation: Patient receives $90 per visit up to a total of $990.
    Co-management: No co-management.
    Sioux Falls Lead Contact: Allie Winter allie.winter@vancethompsonvision.com 605-371-7077

GLAUCOMA RESEARCH

None at this time.


PRESBYOPIC RESEARCH

Oculos OPI-NYPX-301 - COMING SOON

Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) asa Single Agent and With Adjunctive Low-Dose Pilocarpine HydrochlorideOphthalmic Solution 0.4% in Subjects With Presbyopia

Santen

  • Good Candidate: Persons between the ages of 47- 55 years with a diagnosis of Presbyopia in both eyes.
  • About Study: The purpose of this clinical study is to determine how safe and effective this investigational study drug (eye drop) is, and to see how well it works to treat Presbyopia
  • Which eye: both eyes
  • How long is the study: 3 months
  • How many visits: 7 visits
  • Cost to patient: No cost to patient
  • Compensation: Up to $875 ($125 per completed visit)
  • Co-management: No Co-management
  • Lead Contact: Elle Malmanger elle.malmanger@vancethompsonvision.com 605-371-7083

VISUS Therapeutics, Inc. VT-003

  • Good Candidate: Persons between 45 and 80 years of age and have been diagnosed with presbyopia.
  • About Study: The purpose of this study is to assess the safety of the study drug, BRIMOCHOLTM PF and Carbachol PF, and their efficacy (whether it works) in people with presbyopia.
  • Which eye: Both eyes
  • How long is study: 1 years
  • How many visits: 6 visits
  • Cost to patient: No additional costs. You and/or your insurance may be responsible for any routine/standard procedures which are not part of the study.
  • Compensation: Up to $1,560.00 for completed visits.
  • Co-management: No co-management
  • Sioux Falls Lead Contact : Jason Meyer jason.meyer@vancethompsonvision.com 605-371-7064


CORNEA RESEARCH

Glaukos Crosslinking GLK-202-02 -COMING SOON

A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus

TreFoil TTHX-901 (Fuchs' Dystrophy)

Good Candidate: Three options;

  1. Patient with ocular condition that could benefit from TTHX1114 injections

  2. Cataract patient at high-risk of corneal edema following CAT surgery

  3. Patient with FECD scheduled for DSO
    • **Fellow eye must have 20/100 or better for all three options

  • About Study: open-label, evaluate safety/efficacy of TTHX1114
  • Which eye: One eye
  • How long is study: 3 months for options 1 & 2, 1 year for option 3
  • How many visits: 7-11
  • Cost to patient: Injections are free, CAT surgery billed to insurance
  • Compensation: $525-625
  • Co-management: No Co-management
  • Sioux Falls Lead Contact: Rebekah Tuchscherer rebekah.tuchscherer@vancethompsonvision.com 605-705-3517

Claris CSB-C20-003

  • Good Candidate: Subjects 18 years of age and older who have been diagnosed with stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer) Neurotrophic Keratitis (NK)
  • About Study: The purpose of this study is to compare the safety and effectiveness of the study product, CSB.001 ophthalmic solution 0.1% to placebo when treating stage 2 and 3 Neurotrophic Keratitis.
  • Which eye: One eye. Study eye determined by your Dr.
  • How long is study: 2 phases. 8-10 weeks per phase.
  • How many visits: 2 phases, 9-10 visits per phase. Not all subjects will complete both phases
  • Cost to patient: No cost to patient
  • Compensation: up to $2000 for completed visits. (up to $1000 per phase), mileage compensation up to $250/visit if over 50 miles round trip
  • Co-management: No Co-management
  • Lead Contact: Brandon Joffer brandon.joffer@vancethompsonvision.com 605-361-7083


REFRACTIVE RESEARCH


STAAR CP-022 EVO/EVO-ICL

  • Good Candidate: Subject 21 - 45 years old with Myopia ranging from -3.00 D to ≤ -20.00 D spherical equivalent, Up to 4.00 D of astigmatism, Anterior chamber depth 3.00 mm or more, generally healthy eyes.
  • About Study: Post-approval study assessing the rate of early IOP increases after EVO/EVO+ICL implantation
  • Which eye: Both eyes
  • How long is study: 2-3 weeks
  • How many visits: 7 visits
  • Cost to patient: Patient pays $500 per eye, $1000 total
  • Compensation: None
  • Co-management: No co-management.
  • Lead Contact: A’Lece Mathison, alece.mathison@vancethompsonvision.com 605-371-7049

Bausch and Lomb 906 Hyperopic LASIK

  • Good Candidate: At least 22 years old with hyperopia. Sphere range +1.00 D to +4.00 D with or without cylinder up to +2.00 D and max MRSE of +5.00 D. Stable refraction (change of less than or equal to +/- 0.50 D in MRSE) for at least 12 months. UCDVA 20/40 or worse. Pupil size less than 7.0mm.
  • About Study: A Study to Investigate the Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
  • Which eye: Both eyes - must agree to emmetropia in both eyes
  • How long is study: 1 year
  • How many visits: 9 visits over 12 months.
  • Cost to patient: Procedure is performed at no cost to patient.
  • Compensation: Subject will be compensated up to $480.00, in addition to free LASIK.
  • Co-management: No co-management.
  • Lead Contact: Brandon Joffer brandon.joffer@vancethompsonvision.com 605-371-7068


Alcon Contura LASIK - IIT

  • Good Candidate: Age 21-38 with myopia up to -8.00 D, with or without cylinder up to 3.00 D, and are eligible for Contura (topo-guided) LASIK. Max treated MRSE: -9.00 D.About Study: Comparison of visual acuity and quality of life following Contoura with Phorcides compared to WaveLight Wavefront Optimized LASIK.
  • Which eye: Both eyes
  • How many visits: 2 visits
  • Cost to patient: Patient is responsible for all costs associated with LASIK surgery.
  • Compensation: Patient receives $250 after returning for a 3-Month visit.
  • Co-management: Patients can do post-operative care where they prefer.
  • Contacts: Sioux Falls Lead Contact: Jason Meyer jason.meyer@vancethompsonvision.com 605-371-7064




MISCELLANEOUS~DROPS & HEALTHY EYES


None at this time

Fargo Research

CATARACT/LENS Studies

BVI Finevision


  • Good Candidate: Subjects 22 years and older considering intraocular surgery to remove your cataracts
  • About study: The purpose of the study is to evaluate the safety of the FINEVISION HP Trifocal IOL and how well it works compared to an FDA-approved intraocular lens
  • Which eye: Both eyes
  • How long is study: 12 months
  • Number of visits: 11 visits
  • Cost to the patient: The study visits, study IOLs and study-related procedures, other than your cataract surgery, will be provided at no cost to you or your insurance company.
  • Compensation: Up to $550 for completed visits
  • Co-management: None
  • Fargo Lead Contact : Sarah Thiede sarah.thiede@vancethompsonvision.com 701-639-2017

Kowa


  • Good Candidate: At least 18 years old without clinically significant ocular conditions, other than cataracts, that require medication or surgery and are scheduled to undergo standalone cataract surgery. All lens packages eligible. Patients being treated for glaucoma with single medication are eligible (CAIs and ROCK inhibitors excluded).
  • About Study: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week treatment and 14-week extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery. This study is to determine if subjects randomized to K-321 have less natural ECC loss after cataract surgery.
  • Which eye: One eye - determined by investigator
  • How long is study: 4-6 months
  • How many visits: 9-11 visits
  • Cost to patient: Patient and insurance company responsible for costs associated with cataract surgery. Patients receive Ripasudil drops free of charge.
  • Compensation: Patient receives $90 per visit up to a total of $990.
  • Co-management: No co-management.
  • Fargo Lead Contact Sarah Thiede sarah.thiede@vancethompsonvision.com 701-639-2017


PRESBYOPIC

VISUS Therapeutics, Inc. VT-003


  • Good Candidate: Persons between 45 and 80 years of age and have been diagnosed with presbyopia.
  • About Study: The purpose of this study is to assess the safety of the study drug, BRIMOCHOLTM PF and Carbachol PF, and their efficacy (whether it works) in people with presbyopia.
  • Which eye: Both eyes
  • How long is study: 1 years
  • How many visits: 6 visits
  • Cost to patient: No additional costs. You and/or your insurance may be responsible for any routine/standard procedures which are not part of the study.
  • Compensation: Up to $1,560.00 for completed visits.
  • Co-management: No co-management
  • Fargo Lead Contact : Alyson Saville alyson.saville@vancethompsonvision.com 701-809-9905


CORNEA RESEARCH

TreFoil TTHX-901 (Fuchs' Dystrophy)

Good Candidate: Three options;

  1. Patient with ocular condition that could benefit from TTHX1114 injections

  2. Cataract patient at high-risk of corneal edema following CAT surgery

  3. Patient with FECD scheduled for DSO
    • **Fellow eye must have 20/100 or better for all three options

  • About Study: open-label, evaluate safety/efficacy of TTHX1114
  • Which eye: One eye
  • How long is study: 3 months for options 1 & 2, 1 year for option 3
  • How many visits: 7-11
  • Cost to patient: Injections are free, CAT surgery billed to insurance
  • Compensation: $525-625
  • Co-management: No Co-management
  • Fargo Lead Contact: Sarah Thiede sarah.thiede@vancethompsonvision.com 701-639-2017

Avedro Cross Linking ACP-KXL-401

  • Good Candidate: at least 18 years of age, have corneal ectasia after refractive surgery (such as LASIK, PRK, and planning to have corneal collagen cross-linking, or had cross-linking within the past 90 days.
  • About Study: You may be eligible to take part in this observational registry study because you have been diagnosed with corneal ectasia after refractive surgery (such as LASIK or PRK) and you are planning, or have had, corneal collagen cross-linking procedure performed
  • Which eye: One or both eyes
  • How long is study: 3 years
  • How many visits: 5-7 visits over 36 months. (subjects may enroll at month 3)
  • Cost to patient: You or your medical insurance company may be required to pay up to $6,750.00 for the cost of the treatment, medications prescribed by the study doctor during the course of the study, and for any additional standard medical care given during this research study.
  • Compensation: Subject will be compensated up to $600.00.
  • Co-management: No co-management
  • Fargo Lead Contact: Sarah Thiede sarah.thiede@vancethompsonvision.com 701-639-2017


REFRACTIVE


Alcon Contura LASIK - IIT

  • Good Candidate: Age 21-38 with myopia up to -8.00 D, with or without cylinder up to 3.00 D, and are eligible for Contura (topo-guided) LASIK. Max treated MRSE: -9.00 D.
  • About Study: Comparison of visual acuity and quality of life following Contoura with Phorcides compared to WaveLight Wavefront Optimized LASIK.
  • Which eye: Both eyes
  • How long is study: 3 months
  • How many visits: 2 visits
  • Cost to patient: Patient responsible for all costs associated with LASIK surgery.
  • Compensation: Patient receives $250 after returning for a 3-Month visit.
  • Co-management: Patients can do post-operative care where they prefer.
  • Contacts: Fargo Lead Contact: Laida Zimmel laida.zimmel@vancethompsonvision.com 701-566-5628

MISCELLANEOUS~DROPS & HEALTHY EYES

None at this time

BOZEMAN RESEARCH

CATARACT/LENS Studies

BVI Finevision


Good Candidate: Subjects 22 years and older considering intraocular surgery to remove your cataracts

About study: The purpose of the study is to evaluate the safety of the FINEVISION HP Trifocal IOL and how well it works compared to an FDA-approved intraocular lens

Which eye: Both eyes

How long is study: 12 months

Number of visits: 11 visits

Cost to the patient: The study visits, study IOLs and study-related procedures, other than your cataract surgery, will be provided at no cost to you or your insurance company.

Compensation: Up to $550 for completed visits

Co-management: None

Bozeman Lead Contact: Briana Parker briana.parker@vancethompsonvision.com 406-219-0344


Kowa

Good Candidate: At least 18 years old without clinically significant ocular conditions, other than cataracts, that require medication or surgery and are scheduled to undergo standalone cataract surgery. All lens packages eligible. Patients being treated for glaucoma with single medication are eligible (CAIs and ROCK inhibitors excluded).
About Study: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week treatment and 14-week extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery. This study is to determine if subjects randomized to K-321 have less natural ECC loss after cataract surgery.
Which eye: One eye - determined by investigator
How long is study: 4-6 months
How many visits: 9-11 visits
Cost to patient: Patient and insurance company responsible for costs associated with cataract surgery. Patients receive Ripasudil drops free of charge.
Compensation: Patient receives $90 per visit up to a total of $990.
Co-management: No co-management.
Bozeman Lead Contact: Briana Parker briana.parker@vancethompsonvision.com 406-219-0344

CORNEA RESEARCH

Glaukos Crosslinking GLK-202-02 -COMING SOON

Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus



Avedro Cross Linking ACP-KXL-401

Good Candidate: at least 18 years of age, have corneal ectasia after refractive surgery (such as LASIK, PRK, and planning to have corneal collagen cross-linking, or had cross-linking within the past 90 days.

About Study: You may be eligible to take part in this observational registry study because you have been diagnosed with corneal ectasia after refractive surgery (such as LASIK or PRK) and you are planning, or have had, corneal collagen cross-linking procedure performed

Which eye: One or both eyes

How long is study: 3 years

How many visits: 5-7 visits over 36 months. (subjects may enroll at month 3)

Cost to patient: You or your medical insurance company may be required to pay up to $6,750.00 for the cost of the treatment, medications prescribed by the study doctor during the course of the study, and for any additional standard medical care given during this research study.

Compensation: Subject will be compensated up to $600.00.

Co-management: No co-management

Bozeman Lead Contact: Briana Parker briana.parker@vancethompsonvision.com 406-219-0344


REFRACTIVE


Alcon Contura LASIK - IIT

Good Candidate: Age 21-38 with myopia up to -8.00 D, with or without cylinder up to 3.00 D, and are eligible for Contura (topo-guided) LASIK. Max treated MRSE: -9.00 D.

About Study: Comparison of visual acuity and quality of life following Contoura with Phorcides compared to WaveLight Wavefront Optimized LASIK.
Which eye: Both eyes
How long is study: 3 months
How many visits: 2 visits
Cost to patient: Patient responsible for all costs associated with LASIK surgery.
Compensation: Patient receives $250 after returning for a 3-Month visit.
Co-management: Patients can do post-operative care where they prefer.
Contacts: Bozeman Lead Contact: Briana Parker briana.parker@vancethompsonvision.com 406-219-0344

Omaha Research

CATARACT/LENS Studies

RxSight 029

Good Candidate: Subjects Age between 40 and 80 with cataracts affecting their vision

About Study: The purpose of this study is to further evaluate the safety of an approved intra-ocular lens (IOL) called RxSight Light Adjustable Lens (LAL) and a device called Light Delivery Device (LDD)

Which eye: OD or OS, randomized

How long is study: 6 months

How many visits: 7 visits for control group and up to 12 for LAL group

Cost to patient/financial: standard cataract surgery billed to insurance, all study related exams and procedures are no additional cost (i.e. LAL LDD treatments and lock-ins)

Compensation: $450 total, no mileage, fine tune included

Co-management: none

Omaha Lead Coordinator: Sarah Hartnett sarah.hartnett@vancethompsonvision.com 402-899-8020

Kowa

Good Candidate: At least 18 years old without clinically significant ocular conditions, other than cataracts, that require medication or surgery and are scheduled to undergo standalone cataract surgery. All lens packages eligible. Patients being treated for glaucoma with single medication are eligible (CAIs and ROCK inhibitors excluded).
About Study: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week treatment and 14-week extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery. This study is to determine if subjects randomized to K-321 have less natural ECC loss after cataract surgery.
Which eye: One eye - determined by investigator
How long is study: 4-6 months
How many visits: 9-11 visits
Cost to patient: Patient and insurance company responsible for costs associated with cataract surgery. Patients receive Ripasudil drops free of charge.
Compensation: Patient receives $90 per visit up to a total of $990.
Co-management: No co-management.
Omaha Lead Contact: Sarah Hartnett sarah.hartnett@vancethompsonvision.com 402-899-8020



REFRACTIVE

Alcon Contura LASIK - IIT

Good Candidate: Age 21-38 with myopia up to -8.00 D, with or without cylinder up to 3.00 D, and are eligible for Contura (topo-guided) LASIK. Max treated MRSE: -9.00 D.

About Study: Comparison of visual acuity and quality of life following Contoura with Phorcides compared to WaveLight Wavefront Optimized LASIK.
Which eye: Both eyes
How long is study: 3 months
How many visits: 2 visits
Cost to patient: Patient responsible for all costs associated with LASIK surgery.
Compensation: Patient receives $250 after returning for a 3-Month visit.
Co-management: Patients can do post-operative care where they prefer.
Omaha Lead Contact: Amanda amanda.aparo@vancethompsonvision.com

Alexandria Research

CATARACT/LENS Studies

BVI Finevision

  • Good Candidate: Subjects 22 years and older considering intraocular surgery to remove your cataracts
  • About study: The purpose of the study is to evaluate the safety of the FINEVISION HP Trifocal IOL and how well it works compared to an FDA-approved intraocular lens
  • Which eye: Both eyes
  • How long is study: 12 months
  • Number of visits: 11 visits
  • Cost to the patient: The study visits, study IOLs and study-related procedures, other than your cataract surgery, will be provided at no cost to you or your insurance company.
  • Compensation: Up to $550 for completed visits
  • Co-management: None
  • Alexandria Lead Contact: Abby Garofalo abby.garofalo@vancethompsonvision.com 320-391-905

RX SIGHT 029

  • Good Candidate: Subjects Age between 40 and 80 with cataracts affecting their vision
  • About Study: The purpose of this study is to further evaluate the safety of an approved intra-ocular lens (IOL) called RxSight Light Adjustable Lens (LAL) and a device called Light Delivery Device (LDD)
  • Which eye: OD or OS, randomized
  • How long is study: 6 months
  • How many visits: 7 visits for control group and up to 12 for LAL group
  • Cost to patient/financial: standard cataract surgery billed to insurance, all study related exams and procedures are no additional cost (i.e. LAL LDD treatments and lock-ins)
  • Compensation: $450 total, no mileage, fine tune included
  • Co-management: none
  • Alexandria Lead coordinator: Abby Garofalo abby.garofalo@vancethompsonvision.com 320-335-2973

GLAUCOMA STUDIES

No studies at this time